Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2018 Jul;24(7):1313-1321. doi: 10.1016/j.bbmt.2018.04.002. Epub 2018 Apr 10.

Late Effects Screening Guidelines after Hematopoietic Cell Transplantation (HCT) for Hemoglobinopathy: Consensus Statement from the Second Pediatric Blood and Marrow Transplant Consortium International Conference on Late Effects after Pediatric HCT.

Author information

1
Washington University School of Medicine, Pediatric Stem Cell Transplant Program, St. Louis Children's Hospital, St. Louis, Missouri. Electronic address: shalinishenoy@wustl.edu.
2
Meditteranean Institute of Haematology, Rome, Italy.
3
Medical Hematology, Businco Hospial Medical Oncology, Cagliari, Italy.
4
Pediatrics, Washington University, St. Louis, Missouri.
5
Pediatrics, Columbia university Medical Center, New York, New York.
6
Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin.
7
Pediatrics, Leiden University Medical Center, Leiden, The Netherlands.
8
Pediatrics, Emory University, Atlanta, Georgia.
9
Pediatrics, Harvard Medical School, Boston, Massachusetts.
10
Pediatrics, St. Mary's Hospital, London, UK.
11
Pediatrics, Children's Hospital of Los Angeles, Los Angeles, California.
12
Pediatrics, Fred Hutchinson Cancer Center, Seattle, Washington.
13
Pediatrics, UCSF Benioff's Children's Hospital, Oakland, California.

Abstract

Allogeneic hematopoietic cell transplantation (HCT) can halt organ damage and eliminate symptoms in hemoglobin disorders, including sickle cell disease (SCD) and thalassemia major. Managing the residual manifestations of pre-HCT disease complications and the long-term effects of HCT requires systematic monitoring, follow-up and intervention when indicated. Late complications vary with age and disease status at HCT and with transplant variables such as preparative regimen, donor source and compatibility, and immune reconstitution. An international consensus conference sponsored by the Pediatric Blood and Marrow Transplant Consortium in May 2016 entitled "Late Effects Screening and Recommendations Following HCT for Immune Deficiency and Nonmalignant Hematologic Disorders" focused on follow-up after HCT for hemoglobinopathy. An earlier publication from experts who participated in this session described the pathophysiology and spectrum of complications that HCT recipients experience after HCT for SCD and thalassemia major. This companion publication summarizes the consensus reached by this group of experts about long-term follow-up guidelines after HCT for hemoglobinopathy. In addition, these guidelines might also be included in studies of novel curative therapies such as autologous HCT after hematopoietic progenitor stem cell gene modification.

KEYWORDS:

Late effects; Screening; Sickle cell disease; Thalassemia; Transplant

PMID:
29653206
DOI:
10.1016/j.bbmt.2018.04.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center